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Therapeutic intervention with highly active antiretroviral therapy (HAART) can lead to the suppression of HIV viremia below
the threshold of detection for several years. However, impact of HAART on reconstitution of virus-specific immune responses
remains poorly understood. In this study, four macaques were infected with pathogenic SHIVKU. One week postinoculation
two of the four animals were treated with PMPA [9-R-(2-phosphophomethoxypropyl)adenine] daily for 83 days. Two other
macaques, that did not receive treatment, exhibited explosive virus replication accompanied by a near total loss of CD41 T
cells and succumbed to AIDS-related complications within 6 months of infection. These animals did not develop any
virus-specific immune responses. On the contrary, the animals that received PMPA showed transient loss of CD41 T cells
that recovered during the treatment period. The virus burden declined below the level of detection that rebounded soon after
cessation of PMPA therapy. The virus replicated productively for several weeks before both animals controlled the productive
replication of virus. This control of virus replication was found to be associated with the development of virus-specific
neutralizing antibodies, T-helper cells, and CTLs. Although PMPA did not eliminate virus from the animals, it provided them
with enough time to mount virus-specific immune responses that eventually controlled the virus replication in the blood. Our
results suggest that antiretroviral therapy, if initiated early during infection, would help the host in mounting virus-specific
immune responses that might control productive replication of the virus. © 2001 Academic Press
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s
e
c
a
t
t
k
a
t
i
W
1
e
f
s
c
w
1INTRODUCTION
HIV disease results from immunological deterioration
caused by viral elimination of CD41 T cells (Baltimore,
995; de Wolf et al., 1997). Typical of viral disease, the
everity of HIV disease is determined by the rapidity of
irus replication in the host cells and the immune re-
ponses induced by the virus (Harrer et al., 1996; Klener-
an et al., 1996; Bariou et al., 1997; Pontesilli et al., 1997;
gg et al., 1998; Betts et al., 1999). Failure in the devel-
opment of the immune responses results in acutely fatal
disease seen in some infants (Connor et al., 1987). Lack
f consistent virus-specific immune responses have also
een correlated with rapid progression of disease in
IV-1-infected adults (Hay et al., 1999). However, in most
ases of infection in adults, virus-controlling immune
esponses do develop (Koup et al., 1994; Borrow et al.,
1994; Safrit and Koup, 1995; Wilson et al., 1997; Letvin,
1998; Kalams et al., 1999), but eventually they fail to keep
the virus under control. HIV-1 rapidly mutates during
Results of this study were presented at the XIIIth International AIDS
Conference, Durban, South Africa, July 9–14, 2000 (Abstract No.
MoOrA101).s
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97infection, resulting in the generation of viruses that can
escape immune recognition (Phillips et al., 1991; Borrow
et al., 1997; McMichael and Phillips, 1997; Betts et al.,
1997; Borrow and Shaw, 1998; Goulder et al., 1999; Wil-
on et al., 1999). Successful containment of the AIDS
pidemic will ultimately require an effective vaccine that
ould prevent spread of HIV-1. However, development of
n effective vaccine would be contingent upon charac-
erization of definitive immunological correlates of pro-
ection during HIV-1 infection that remains largely un-
nown.
The development of highly active antiretroviral ther-
py (HAART) has provided an aid to the immune sys-
em to keep the virus contained, although this requires
ndefinite continuation of therapy (Chun et al., 1997;
ong et al., 1997; Finzi et al., 1997, 1999; Zhang et al.,
999). Nevertheless, HAART has created hope for the
ventual development of immunological control. In the
ew cases in which therapy has been discontinued,
ome of the individuals succumbed to virus recrudes-
ence (Jubault et al., 1998; Staszewski et al., 1998),
hile others kept the virus under control (Vila et al.,
997; Lisziewicz et al., 1999). Recently, this control was
hown to be associated with the development of ap-
ropriate antiviral immune responses (Oritz et al.,
0042-6822/01 $35.00
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98 KUMAR ET AL.1999; Lu and Andrieu, 2000; Binley et al., 2000). How-
ever, the exact nature of these immune responses
remains to be identified.
We used the SHIVKU model of HIV disease to explore
this question. The genome of SHIVKU encodes the env,
tat, rev, vpr, and vpu of HIV-1 in a background of
SIVmac and provides an excellent model of HIV dis-
ease because it not only has many of the genes of HIV
but it also causes the rapid elimination of CD41 T cells
and AIDS in macaques (Joag et al., 1996, 1998a). Most
animals infected with SHIVKU fail to develop immune
responses and succumb to acute disease. Recently,
we used the nucleoside analog PMPA [9-R-(2-phos-
hophomethoxypropyl)adenine] that has been shown
o be effective against HIV-1 (Suo and Johnson, 1998)
nd SIV (Tsai et al., 1995) as a therapeutic agent in the
HIVKU/macaque model of AIDS. Treated animals con-
rolled virus replication and showed recovery of CD41
T cells. After cessation of PMPA, virus rebounded in
these animals, only to replicate productively for a few
months before it was controlled, even in the absence
of any treatment. These animals developed virus-spe-
cific cellular and humoral immune responses that
were perhaps associated with the indefinite suppres-
sion of viral replication. In this report we characterized
the immune responses associated with control over
virus replication.
RESULTS
Clinical outcome of SHIVKU-2 infection in untreated
ontrol rhesus macaques
Four rhesus macaques were inoculated intravenously
ith 104 animal infectious doses of pathogenic SHIVKU-2.
his is the same stock of virus that was used in our
revious studies (Joag et al., 1998a). The SHIVKU-2 is a
highly pathogenic virus and acute infection by SHIVKU-2 is
characterized by highly productive replication in the lym-
phoid system and massive elimination of CD41 T cells
within 3 to 4 weeks of infection. The animals developing
acute disease caused by SHIVKU-2 do not develop virus-
specific immune responses and succumb to SHIV-in-
duced AIDS within 6 to 8 months after infection. We
infected more than 20 animals with this virus and uni-
formly achieved this result, with one exception that de-
veloped chronic disease. In the present study, two con-
trol animals (57/W and 57/Y) showed massive virus rep-
lication as determined by high-viral RNA load in plasma
(Fig. 1A) and frequency of infected cells in PBMC (Fig.
1B), followed by near total loss of CD41 T cells (Fig. 1C).
either of these two animals developed virus-specific
ellular or humoral immune responses to the virus. The
ontrol animals were euthanized at Weeks 26 and 27
ostinoculation (p.i.) because of deteriorating clinical
onditions. At necropsy, these animals had pneumonia
nd encephalitis. This acute clinical course in theseanimals was typical of pathogenic SHIVKU-2 infection that
we observed in other animals inoculated with the same
virus stock.
Long-term modulation of virus replication and
regeneration of CD41 T cells after PMPA therapy
The two other macaques (45/P and 45/Q) were in-
oculated with SHIVKU-2 and treated with PMPA for 83
days, starting from Day 7 p.i. These animals were
monitored for viral loads in plasma (Fig. 1D), PBMC-
associated viral load (Fig. 1E), and CD41 T-cell profiles
(Fig. 1F). The time course of study can be divided into
three periods: postinoculation but pretreatment (Days
0–7 postinfection), on treatment (Days 8–90 postinfec-
tion), and off treatment (Day 91 and onward). On Day 7,
when PMPA treatment was initiated, the plasma viral
loads in both animals were .107 copy Eq/ml, and the
cell-associated viral loads were 1000 infected cells/
106 PBMC. After commencement of PMPA treatment,
the viral burden in plasma, as determined by real-time
RT-PCR, declined to below the threshold of detection
by Week 4 p.i. However, cell-associated virus in both
macaques was detectable at Week 4 p.i. but became
undetectable in the following weeks. However, treat-
ment did not result in the clearance of the infection, as
reemergent virus appeared in the blood soon after the
discontinuation of PMPA. The reemergent virus repli-
cated productively for 29 weeks in 45/P and 25 weeks
in 45/Q, but never attained the peak levels observed
prior to treatment (Fig. 1E). The peak viral load in
plasma during the rebound phase was between 1 and
15 3 104 copy Eq/ml, thus showing at least 3–4 log-
fold reduction compared to that observed during the
pretreatment phase. Following the low level of resur-
gence, the viral load again declined below the level of
detection and remained there throughout the study.
Both animals showed a significant decline in CD41
T-cell counts during the first week postinfection, followed
by a substantial recovery in the cell count during treat-
ment. The animals then underwent another round of
CD41 T-cell loss (though less significant than that of the
first round) after PMPA was discontinued, that coincided
with increased viral load (Figs. 1D and 1F). Both animals
again showed efficient recovery in CD41 T-cell popula-
ion and achieved a level higher than the preinfection
evel. At Week 66 postinfection, CD41 T-cell counts in
macaque 45/P and 45/Q were 3546 and 1152 cells/ml of
blood, respectively.
Evolution of cellular and humoral immune responses
in macaques infected with SHIVKU-2 and treated with
PMPAOur observation that the PMPA-treated animals
(45/P and 45/Q) controlled virus replication in the
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FIG. 1. Plasma viral RNA load, cell-associated viral burdens, and CD
MPA-treated macaques (D, E, and F). The macaques were infected w
s described under Materials and Methods. Macaques were monitored
that cross-reacts with rhesus CD4. The absolute number of CD41 T c
subset with absolute number of lymphocytes/ml from complete blood c
and cell-associated virus load by determining frequency of infectiousomenon never encountered in the virus control ani-
als, prompted us to investigate whether the animals
m
rad developed virus-specific immune responses that
ll profile in control untreated macaques (A, B, and C, respectively) and
IVKU-2 and two of the four infected macaques were treated with PMPA
ir CD41 T-cell counts by staining with a MAb to human CD4 molecule
of blood was calculated by multiplying the percentage of lymphocyte
BC). The plasma viral RNA load was determined by real-time RT-PCR
described under Materials and Methods.41 T-ce
ith SH
for the
ells/mlight be responsible for containment of the virus
eplication.
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100 KUMAR ET AL.Evolution of envelope-specific antibody responses in
macaques treated with PMPA that were also directed
against neutralization epitope(s) on SHIVKU-2 envelope
We tested 13 sequential plasma samples from the two
macaques (45/P and 45/Q) that were infected with
SHIVKU-2 and treated with PMPA, and eight samples from
the control animals (57/W and 57/Y) that were infected
with the same virus but not treated with PMPA. These
samples were tested for the presence of envelope-spe-
cific antibodies in Con A ELISA and also for their ability
to neutralize SHIVKU-2 in a neutralization assay. Appropri-
te controls were used to demonstrate that the Con A
LISA detected only envelope-specific antibodies. These
ncluded negative results from binding of FA2 antibody to
apture antigen in this system. The FA2 antibody is a
ouse-MAb against SIV-Gag (P-27) protein that does not
ind with the SHIVKU-2 envelope in this assay, suggesting
envelope specificity of this system (data not shown). The
control animals (57/W and 57/Y) did not develop detect-
able antibodies against the SHIVKU-2. However, it is pos-
sible that these control animals might have developed
antibodies against other viral proteins that were not
tested in the present study. On the contrary, the two
animals that were treated with PMPA after SHIVKU-2 inoc-
ulation developed detectable antibodies at Week 6
postinfection. The antibody levels continued to increase
until Week 21 p.i. and then followed a different course of
evolution in the two animals. In macaque 45/P, the anti-
body level increased until Week 30 and then declined
slightly at Week 34, followed by a further increase in the
level of envelope-specific antibodies that lasted through-
out the observation period. In the other animal (45/Q)
envelope-specific antibodies increased until Week 27,
followed by a gradual decline from Weeks 27 to 34. The
antibody level increased again and attained peak levels
at Week 42 postinfection (Fig. 2A).
We next determined the maturation process of enve-
lope-specific antibodies in the two PMPA-treated ani-
mals. It was previously reported that the maturation of
envelope-specific antibodies is slow and takes about
5–6 months in SIV (Cole et al., 1997a,b, 1998) and SHIV
(Cole et al., 1998) infected macaques. Note that SHIVs
used in the earlier studies were precursor to the highly
pathogenic SHIVKU-2 and the animals infected with those
iruses were reported to mount virus-specific immune
esponses (Joag et al., 1997; Cole et al., 1998). We sought
o address whether a therapeutic intervention would
ake any difference in the course of antibody matura-
ion. In this study, antibody titers continued to increase
hroughout the observation period, suggesting that mat-
ration time was longer than that observed in earlier
tudies (Cole et al., 1998). However, the qualitative
hanges such as conformational dependence (Fig. 2B)
nd antibody avidity (Fig. 2C) were almost similar. We
ested nine samples that were positive for envelope-
s
ipecific antibodies for their conformation dependence
nd avidity. At Week 6 p.i., both animals had antibodies
hat were predominantly directed against conformation-
ependent epitope(s) on the envelope. However, the
onformational dependence of the envelope-specific an-
ibodies decreased from a high of 6 to an average
FIG. 2. Evolution of envelope-specific antibody responses in control
and PMPA treated macaques. Longitudinal samples were obtained
from four rhesus macaques at the indicated time after inoculation with
SHIVKU-2. The end-point titer (A), conformational dependence (B), and
vidity index (C) of envelope-specific antibodies were determined in
on-A ELISA as described under Materials and Methods. The samples
rom control animals did not develop envelope-specific antibodies and,
herefore, were not used for determination of conformational depen-
ence and avidity index. The neutralizing antibody titers were deter-
ined by testing sequential heat-inactivated plasma samples (in qua-
ruplicate). Different dilutions of plasma samples were preincubated
ith virus before addition of indicator cells. They were cultured for 7
ays and then scored for cytopathic effects. The results are presented
s antibody titer for the dilution that neutralized the virus in all four
xperimental wells (D).teady-state ratio of about 2 in both animals by approx-
mately 4 months postinfection and continued to persist
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101IMMUNE RESPONSES IN SHIV-INFECTED PMPA-TREATED MACAQUESat the same level for the following 2 months. The con-
formation dependence of the antibodies in both animals
declined once again to a ratio of about 1.7, that persisted
throughout the observation period. In addition, changes
in antibody avidity were also evident in both animals.
While low-avidity antibodies were present in the begin-
ning (Week 6, 12% in 45/P and 10.5% in 45/Q), the avidity
index gradually increased and reached a level of 68 and
56% in 45/P and 45/Q, respectively.
We tested the same 13 plasma samples for their po-
tential to neutralize SHIVKU-2. As shown in Fig. 2D, both
animals developed SHIVKU-2-specific neutralizing anti-
bodies that appeared only in the posttreatment period.
The neutralizing antibody titers increased until Weeks 27
and 34 postinfection in 45/P and 45/Q, respectively (peak
neutralizing Ab titers 1/40 in both animals). Once the
maximum titers were achieved they were maintained
throughout the observation period. Two control animals
did not develop neutralizing antibodies.
Animals infected with SHIVKU-2 and treated with PMPA
induced strong T-helper responses
Peripheral blood mononuclear cells (PBMC) from 45/P
and 45/Q were tested for their potential to proliferate in
response to viral antigens. They were tested at 10 differ-
ent time points starting from Week 4 p.i. This assay was
specific, as PBMC from none of the six uninfected ani-
mals responded to this antigen when subjected to sim-
ilar stimulation (results not shown). As shown in Fig. 3,
both animals developed antigen-specific proliferative re-
sponses that were first detectable at Week 9 postinfec-
tion, suggesting that MHC class II-restricted virus-spe-
cific Th cells were primed at or before Week 9. The
T-helper responses peaked at Week 27, followed by a
gradual decline until Week 46 in both macaques, and
then roughly leveling off for the remainder of the obser-
FIG. 3. Development of virus-specific T-helper cells in macaques
noculated with SHIVKU-2 and treated with PMPA. The sequential periph-
ral blood mononuclear cells from control and PMPA-treated animals
ere cultured in the presence of whole virus antigens at indicated time
oints and proliferative responses were measured as described under
aterials and Methods. The results are presented as stimulation indi-
es obtained from dividing mean CPM in the virus-stimulated wells by
ean CPM in the unstimulated wells.vation period. Two control animals that were infected
with SHIVKU-2 did not develop any T-helper responses.
t
sMacaques 45/P and 45/Q developed MHC-restricted
CD81 CTLs that were directed against Env, Gag, and
Pol proteins
The PBMC from the two animals that were infected
with SHIVKU-2 and treated with PMPA developed potent
CTL responses against the viral proteins, that is, HIV-
1Env, SIV-Gag, and SIV-Pol. The PBMC from these ani-
mals were obtained at Weeks 38 and 54 postinfection
and tested in a 4-h 51Cr-release assay as described
under Materials and Methods. The PBMC effectors were
tested at effector/target (E/T) ratios of 80/1, 40/1, 20/1, and
10/1. The specific lysis against different targets obtained
at the E/T ratio of 40/1 is shown in Fig. 4. Effectors from
both treated macaques showed CTL activity, although
45/P effectors showed stronger specific lysis. On the
contrary, Weeks 12 and 24 PBMC effectors from the two
control animals (57/W and 57/Y) did not show any cyto-
lytic activity against autologous B-LCLs infected with
recombinant vaccinia viruses expressing either HIV-
1Env, SIV-Gag, or SIV-Pol (Figs. 4C and 4D).
These CTLs were characterized by testing for CTL
activity in CD4 and CD8 populations against syngenic
and allogenic targets. Three different effectors (unfrac-
tionated PBMCs, and positively selected CD41 and
D81 T cells) from 45/P and 45/Q were prepared and
tested against autologous B-LCLs cells infected with
different recombinant vaccinia viruses expressing one of
the viral proteins. Unfractionated PBMC effectors were
also tested against allogenic targets prepared in a sim-
ilar fashion as autologous targets. B-LCL from another
rhesus macaque was used as the allogenic target. The
results of this experiment are shown in Fig. 5A. The
effectors from both macaques recognized and lysed au-
tologous targets infected with the recombinant vaccinia
virus expressing one of the viral proteins but not the
allogenic targets infected with recombinant vaccinia vi-
ruses, suggesting that CTL activity was MHC restricted.
The CD81, but not the CD41, T-cell fraction from PBMCs,
when used as effectors, exhibited CTL activity (Fig. 5B).
DISCUSSION
The contrasting pathogenesis of SHIVKU infection be-
tween untreated versus PMPA-treated infected animals
illustrated that, whereas the untreated animals failed to
develop any antiviral immune responses and succumbed
to full-blown productive infection with complete loss of
CD41 T cells and AIDS, treatment caused sufficient con-
ainment of viral replication so as to allow the animals to
evelop strong humoral and cellular immune responses
o the virus. These were associated with indefinite cur-
ailment of virus replication after treatment had stopped.
his study corroborates with a recent finding in a small
roup of HIV-infected individuals on HAART, who electedo discontinue the therapy and whose immune re-
ponses alone were associated with prolonged curtail-
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102 KUMAR ET AL.ment of HIV-1 replication (Oritz et al., 1999). In two recent
studies the macaques infected with SIV and treated with
PMPA and macaques infected with SHIV-RT and treated
with another RT inhibitor were shown to develop virus-
specific immune responses that were maintained better
in treated animals than in untreated controls (Lifson et
al., 2000; Mori et al., 2000). However, development of the
mmune responses in control animals in these studies
ndermined the significance.
Our study provides a suitable model to evaluate the
mmunological correlates of resistance to HIV-1 replica-
ion after discontinuation of antiretroviral therapy. The
ack of cellular and humoral immune responses in con-
rol animals was clearly associated with PMPA treat-
ent. At present we do not know whether all of the
mmune responses generated by macaques 45/P and
5/Q were essential for suppression of SHIVKU replica-
ion. It is likely that both humoral and cellular immune
esponses in these animals contributed to the effective
ontrol of virus replication during the posttreatment pe-
iod. Our results revealed that neutralizing antibody ap-
FIG. 4. Cytotoxic T-lymphocyte activities in macaque 45/P (A), 45/Q (B
ere tested against autologous B-LCLs infected with recombinant vacc
pecific lysis obtained at effector/target ratio of 40/1. The control targ
wild-type vaccinia.eared in the circulation soon after cessation of PMPA
herapy and persisted there at quite high level through-out the observation period. These antibodies perhaps
contributed to the elimination of free viruses in the
plasma, which is evident from our observations that,
although SHIVKU-2 rebounded in both animals, viral repli-
cation was promptly brought under control by host-in-
duced immune responses. Neutralizing antibodies were
previously shown to protect macaques against patho-
genic SHIV infection (Foresman et al., 1998; Shibata et
al., 1999; Mascola et al., 1999) and, therefore, emergence
of neutralizing antibodies seems to be of paramount
importance in containment of viral replication in PMPA-
treated animals.
The role of proliferative antigen-specific CD41 T cells
emains to be clarified. On one hand these cells provide
preferred source for virus replication and lead to an
cute infection (if insufficient or incorrect effector mech-
nisms were in place prior to virus exposure) (Steger et
l., 1999). However, T-helper cells have also been found
o be associated with control of viremia in HIV-1-infected
ndividuals (Rosenberg et al., 1997) and with production
of b-chemokines (Gauduin et al., 1999) that are known to
(C), and 57/Y (D) against Env, Gag, and Pol proteins. The CTL effectors
us expressing HIV-1Env, SIV-Gag, or SIV-Pol. The results are shown as
sents specific lysis obtained using autologous B-LCLs infected with), 57/W
inia virinhibit virus replication (Garzino-Demo et al., 1999;
Maeda et al., 1999). The lack of strong virus-specific
S
a
ulated
a The spe
103IMMUNE RESPONSES IN SHIV-INFECTED PMPA-TREATED MACAQUEST-helper responses in HIV infection is also thought to be
responsible for defects in the immune repertoire in in-
fected individuals, suggesting an important role for Th
responses (Lane et al., 1985; Wahren et al., 1987; Berzof-
sky et al., 1988; Clerici et al., 1989). In the present study,
T-helper response was first detected at Week 9 postin-
fection that increased until Week 27, followed by a de-
cline from Weeks 36 to 46. The Th response was then
maintained throughout the observation period of 58
weeks. The reason for the decline in T-helper responses
between Week 36 and Week 46 is not clearly understood.
Nevertheless, the T-helper responses were sustained
throughout the study and might have contributed to con-
trol of SHIV-induced viremia as observed previously in
HIV-1-infected individuals (Rosenberg et al., 1997).
The virus-specific T-helper cells were also shown to
be important for the maintenance of efficient CTL re-
sponses. This was first shown in the LCMV model, in
which CD4 depletion resulted in reduced CTL responses
and increased viremia (Battegay et al., 1994; Matloubian
et al., 1994). Recently, a strong correlation was observed
between T-helper responses and CTL responses
(Kalams and Walker, 1998; Kalams et al., 1999). Our data
FIG. 5. CTL activity in SHIVKU-2-infected and PMPA-treated macaqu
IV-Gag-, and SIV-Pol-specific CTL activity is MHC restricted. Week
llogenic targets infected with recombinant vaccinia virus expressing o
PBMC (Unfx) and positively selected CD41 and CD81 T cells were stim
gainst autologous B-LCL infected with HIV-1Env, SIV-Gag, or SIV-Pol.also suggest that CTL responses might be important for
indefinite curtailment of the virus, as observed in several sstudies reported previously (Johnson et al., 1997, 1999).
However, we cannot speculate about the kinetics of CTL
responses, as these studies were not initiated until 38
weeks after infection.
The SHIVKU model reported here complements two
other macaque models of HIV infection/disease. Studies
using HIV-2287 showed similar results, that infected ani-
mals treated with another antiretroviral drug (d4T) did not
lose CD41 T cells. These animals were able to modulate
viral replication favorably and survived longer than con-
trol animals that did not receive any treatment (Watson et
al., 1997). On the contrary, in a previously reported study,
PMPA in the SIV/macaque model caused curtailment of
virus replication, but upon cessation of therapy, virus
replication rebounded to pretreatment levels (Van
Rompay et al., 1996), simulating the phenomenon that
was seen in several cases of HIV-1-infected individuals
who withdrew from HAART (Jubault et al., 1998; Stasze-
wski et al., 1998). This difference in findings can be
ascribed to the time when treatment was initiated. In the
present study, PMPA treatment was initiated within 1
week after infection, whereas in the earlier study PMPA
treatment was initiated during late-stage SIV infection
HC restricted and mediated by CD81 T lymphocytes. (A) HIV-1Env-,
C effectors were analyzed for CTL activity against autologous and
e proteins. (B) CTL activity is mediated by CD81 T cells. Unfractionated
as described under Materials and Methods and tested for CTL activity
cific lysis shown here was obtained at an effector/target ratio of 40/1.es in M
58 PBM
ne of th(Van Rompay et al., 1996). In several other studies it was
hown that early short-term drug treatment of macaques
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104 KUMAR ET AL.infected with SIV or RT-SHIV can modulate the course of
disease (Novak et al., 1997; Van Rompay et al., 1999;
Lifson et al., 2000; Mori et al., 2000; Rosenwirth et al.,
2000). The present study provides support to the concept
that combination of HAART with a therapeutic vaccine
that can induce long-lasting virus-specific immune re-
sponses would be effective in controlling HIV replication
without the need for indefinite reliance on drug therapy.
Although we used only four animals in this study, results
obtained from those animals provide an interesting pos-
sibility that specific therapy could lead to long-term im-
munological control of SHIV infection in macaques. This
concept should be tested in larger cohorts of animals
using different viruses as well as different antiretroviral
drugs.
MATERIALS AND METHODS
Viruses, animals, and challenge stock
The development of pathogenic SHIVKU-2 was previ-
ously described (Joag et al., 1998a). This virus was grown
in PHA-stimulated rhesus PBMCs and titrated using
C8166 cells. The titer of the challenge virus stocks was
104.9 TCID50/ml. Herpesvirus papio stock was obtained by
rowing the S594 cell line, which was generously pro-
ided by Dr. N. Letvin. This cell line is an immortalized
-cell line productively infected with the baboon Herpes-
virus papio (Rabin et al., 1977). The vaccinia viruses,
AbT299 (expressing HIV-1BH-10ENV lacking 19 amino ac-
ds starting from positions 42–60 at the amino terminus),
AbT252 (SIVmac251 gag-protein), vAbT258R (SIV-
ac251 pol), and NYCBH (wild type) were kindly pro-
ided by Drs. D. Pancali and G. Mazzara (Therion Bio-
ogics, Cambridge, MA). The recombinant vaccinia virus
tock was propagated in HeLa cells culture. All virus
tocks were maintained at 280°C, except the challenge
irus stock, which was stored in liquid nitrogen.
Four sexually mature rhesus macaques (Macaca mul-
ata) were obtained from the Yerkes Primate Center (At-
anta, GA) and maintained in AAALAC-approved Animal
acility of the University of Kansas Medical Center. The
IH guidelines were followed for maintenance and re-
earch protocols. Prior to the experimental protocol, the
onkeys were quarantined for 6 weeks. During this
eriod, the animals received three tuberculin injections
nd were monitored for hematological and clinical pa-
ameters. The animals were also screened for antibody
rofiles against different viruses, including SIV and
TLV-1. These macaques were inoculated intravenously
ith 1 ml of SHIVKU-2. One week later, two macaques
(45/P and 45/Q) were treated with PMPA (30 mg/kg/day
subcutaneously), daily for 83 days. Two other macaques
(57/W and 57/Y) served as controls and did not receive
PMPA.Infectious cell assay, CD41 T-cell counts, and
quantification of viral load in plasma
All four macaques were periodically monitored for
CD41 T-cell counts and viral loads in the blood by infec-
ious cell assay as described before (Joag et al., 1998a,b;
umar et al., 2000). Briefly, the frequency of infectious
ell was determined by inoculation of serial 10-fold dilu-
ions of PBMC into replicating culture of C8166 cells.
fter 7 days at 37°C, 100-ml aliquots from each of the
wells were inoculated into new wells containing fresh
C8166 cells, which were then observed for development
of cytopathic effects (CPE). Results are expressed as the
number of infectious cells per 106 PBMC. Viral load in
plasma was quantitated by real-time RT-PCR, developed
as described before (Suryanarayana et al., 1998). Briefly,
RNA was isolated from 500 ml plasma and amplified
using SIVgag primer, and quantification was based on
analysis during the exponential phase of amplification.
This assay has a nominal threshold sensitivity of 100
copy Eq/ml of the plasma.
Determination of binding antibody against SHIVKU-2
envelope
Plasma samples from PMPA-treated and control mon-
keys were analyzed for their reactivity to native viral
glycoprotein in a concanavalin A (Con A) ELISA (Robin-
son et al., 1990; Cole et al., 1997a; Kumar et al., 2000).
Triton X-100-treated and density gradient-purified virus
(TX-disrupted gradient-purified virus) was used as the
source of viral antigen. Each well of Immulon II microtiter
plates (Dynatech Labs, Chantilly, VA) was coated with
Con A, and then incubated with viral proteins. The plates
were then blocked with RPMI 1640 containing 10% fetal
bovine serum (FBS, R-10) for 1 h and sequential dilutions
of plasma were added in duplicates. After a 90-min
incubation at 37°C, plates were washed three times with
normal saline Tween (NST; 0.85% NaCl and 0.1% Tween
20). Peroxidase-conjugated anti-monkey IgG (100 ml;
Sigma, St. Louis, MO), diluted 1:10,000 in PBS containing
1% FBS, was added to each well. The plate was incu-
bated at 37°C for 1 h, followed by three washes with
NST. Reaction was developed with ortho-phenylinedia-
mine (OPD), and optical density was measured in a plate
reader (Dynatech Labs) at 490-nm wavelength. Endpoint
titers were calculated from the last dilution whose OD
was twice that of normal monkey plasma at 1/1000 dilu-
tion, or an OD of 0.1, whichever value was greater.
Measurement of conformational dependence of
antibodies
Plasma samples from PMPA-treated macaques were
analyzed for conformation dependence by comparing the
reactivity of circulating antibodies in blood to native and
denatured envelope protein of the virus in Con A ELISA
c105IMMUNE RESPONSES IN SHIV-INFECTED PMPA-TREATED MACAQUES(Cole et al., 1997a; Kumar et al., 2000). The denatured
viral envelope glycoproteins were prepared by treating
TX-disrupted gradient-purified virus with 0.12 M 2-ME
and 8 M urea, to reduce disulfide bonds, followed by
treatment with iodoacetic acid, to irreversibly carboxy-
methylate the reduced sulfahydryl groups. The dena-
tured virus was then extensively dialyzed against phos-
phate-buffered saline (PBS) and concentrated by spin-
ning through a Centricon filter (Millipore). The protein
concentration was determined using the Bio-Rad DC
protein assay (Bio-Rad, Hercules, CA). The plasma dilu-
tion selected for this experiment was the one that gave
an OD between 1 and 1.5. The conformational ratio was
then calculated from the ratio of antibody reactivities to
native versus denatured envelope glycoproteins.
Determination of antibody avidity
The avidity of envelope-specific antibodies was deter-
mined by measuring the resistance of the antigen–anti-
body complex to 8 M urea (Cole et al., 1997a; Kumar et
al., 2000). A given plasma dilution, that gave OD between
1 and 1.5 against SHIVKU-2 envelope, was tested in a Con
A ELISA in two sets of triplicate wells. One set of three
wells was treated with 8 M urea for 5 min after incuba-
tion with primary antibody and then washed four times
with NST (0.85% NaCl and 0.1% Tween 20). The avidity
index was calculated from the ratio of OD490 values
obtained with urea treatment to that obtained with un-
treated wells and multiplied by 100. Antibodies with an
avidity index of ,30% were considered as low avidity,
those with values between 30 and 50% were considered
of intermediate avidity, and those with values .50% were
designated as high avidity.
Determination of neutralizing antibody against
SHIVKU-2
Neutralizing antibody titers in plasma were deter-
mined as described before (Silverstein et al., 2000).
Briefly, serial double dilutions of heat-inactivated plasma,
prepared in RPMI 1640 containing 10% FBS, 5 mM
NaHCO3, and 50 mg/ml gentamicin (R-10), were added in
flat-bottom 96-well plates using four wells per dilution.
Eight TCID50 of SHIVKU-2 virus were added to each well
and the plates were incubated at 37°C for 1 h, followed
by addition of 104 C8166 cells to each well. After 1 week
of incubation at 37°C, each well was individually scored
for cytopathic effect (CPE). The endpoint titer was deter-
mined by the ability of a plasma dilution that neutralized
the virus in all four wells.
Lymphocyte proliferation assay
Sequential PBMC samples from four macaques were
cultured at 105 cells/well in flat-bottom 96-well tissue
4.9ulture plates in 200 ml R-10. Stock SHIVKU-2 (10 TCID50/
ml) was UV-irradiated for 1 h and heat-inactivated at56°C for 3 h. A 20-ml sample of this material was used as
the source of viral antigens. Three wells, each containing
no antigen, served as the negative controls for the ex-
periment and three wells stimulated with 5 mg/ml of Con
A served as the positive controls. Cells were cultured for
5 days, after which each well was pulsed with 1 mCi of
[3H]thymidine (spec. act. 247.9 GBq/mmol; NEN, Boston,
MA). Eighteen hours later, the cells were harvested onto
glass-fiber filter mats by using an automated plate har-
vester (Skatron, Sterling, VA) and [3H]thymidine incorpo-
ration was determined with a microbeta liquid scintilla-
tion counter (Packard Instruments, Meriden, CT). Stimu-
lation indices (SI) were calculated as mean counts per
minute (CPM) in the stimulated wells/mean CPM in the
negative control wells. An SI of greater than 2 was
considered significant (Kumar et al., 2000).
Development of lymphoblastoid B-cell line (B-LCL)
The B-lymphoblastoid cell lines (B-LCLs) were derived
by inoculating PBMCs with Herpesvirus papio (kindly
provided by Dr. N. Letvin, Harvard Medical School, Bos-
ton, MA) for 2 h at 37°C. Cells (105) were then added to
each well of flat-bottom 96-well tissue culture plate. They
were maintained in the presence of 500 ng/ml of cyclos-
porin-A (Sigma) in 200 ml R-10. In approximately 2 weeks’
time the B cells started growing in clumps and were
transferred into 25-ml tissue culture flasks and main-
tained in R-10.
Generation of effector T-cell population and CTL
assay
The methods for preparation of the CTL effectors and
chromium release assay were previously described
(Joag et al., 1998b; Kumar et al., 1999, 2000; Silverstein et
al., 2000; Stipp et al., 2000). Briefly, PBMCs were cocul-
tured with UV-irradiated autologous CD41 T cells in-
fected with SHIVKU (effector/stimulator ratio of 10:1) in
R-10. One week after initial stimulation, the PBMCs were
restimulated and medium was supplemented with IL-2
(100 IU/ml). One week after the second stimulation, the
growing cells were used as effectors in a 4-h chromium-
release assay. B-LCLs infected with recombinant vac-
cinia viruses expressing HIV-1Env, SIV-Gag, or SIV-Pol
(kindly provided by Dr. D. Panicali, Therion Biologics)
were used as targets in the experiments. Two million
target cells were labeled with 100 mCi 51Cr [spec. act. 962
MBq/ml of sodium chromate (Amersham, Cleveland,
OH)] for 2 h and then washed thrice with HBSS. Target
cells (2500/well) were dispensed into each well of 96-
well plates. Effector cells were tested in triplicate at
effector/target (E/T) ratios of 80/1, 40/1, 20/1, 10/1, and 5/1.
Each well received 200 ml R-10. Chromium release was
determined after a 4-h incubation at 37°C by counting
100 ml of supernatant from each well in a Gamma
counter (Packard Instruments). Each experiment had
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vided data for spontaneous lysis, while three wells con-
taining targets and 100 ml of 1% SDS provided data for
maximal lysis. The percentage specific lysis was calcu-
lated as: [(mean CPM in test wells 2 mean CPM in
pontaneous wells)/(mean CPM in maximal wells 2
ean CPM in spontaneous wells)] 3 100.
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